For decades, the standard of care for bowel cancer has been a grueling, predictable cycle: surgery first, then months of ...

Pancreatic ductal adenocarcinoma is one of the deadliest cancer types, with a five-year survival rate of 13%. There are only ...

Three-fourths of patients had cancer-free mediastinal lymph nodes, clear surgical margins ...

Perioperative immunotherapy improves hepatocellular carcinoma outcomes, reducing recurrence risk and enhancing event free ...

New bowel cancer immunotherapy treatment ‘highly effective’ in improving survival rates - A new study found zero relapses ...

Molecular/genomic profiling is expanding precision selection of systemic therapy and may enable immunotherapy-driven organ ...

Researchers developed a compound that activated STING while inhibiting PI3Kγ. The approach reduced immune resistance, limited ...

A new grant from the American Cancer Society (ACS) will fund research into a new strategy for targeting glioblastoma at MUSC ...

Two landmark trials in lung and bowel cancer show that giving immunotherapy before surgery significantly improves survival and may eliminate the need for chemotherapy in select patients. In resectable ...

University of Southampton scientists have made a breakthrough in understanding why some cancers don't respond to immunotherapy treatment, bringing fresh hope that many more people could survive the ...

The deletion of two cancer genes, CHD1 and MAP3K7, improves how well tumours respond to cancer immunotherapy and could be used as biomarkers to help predict which patients are most likely to benefit ...

CHARLOTTE, N.C. — A new study suggests the next big breakthrough in cancer treatment might come from a familiar source. Researchers at University of Florida found that patients with advanced lung or ...